Vadim Pospelov is a genetic researcher and philanthropist. His most significant scientific achievements include a method for slowing down the formation of metastases by means of exosomal therapy and immunotherapy.
Pospelov is a member of the ISEV (International Society for Extracellular Vesicles), the GSEV (German Society for Extracellular Vesicles) and a member of the Board of Directors of the Rehabilitation Association ESPA. He is also the co-founder of a rehabilitation centre in Sapareva-Banja, which will be operated under the partner brand Swissôtel.
He is also the founder of the private charity "Law, Justice and Mercy".
Scientific Head of Laboratory
Early Career
Pospelov studied bioengineering and biomechanics at the N. E. Bauman Moscow State Technical University between 1991 and 1998 and was himself a lecturer there between 1998 and 2005. In his research work, Pospelov initially concentrated on intravascular surgery. In 2002, he applied for his first patent - an endovascular robot.
His acquaintance with the genetic researcher Belokhvostov at the end of the nineties was groundbreaking for Pospelov's further career. Together they founded one of the first private genetic research laboratories in Russia in 1998. Using saliva samples, they determined the genetic predisposition to diseases such as cancer, diabetes as well as genetic childhood diseases such as myopathy. This made them pioneers in genetic diagnostics throughout Russia. In parallel, Pospelov developed a fibre-optic sensor for the hypothermic treatment of tumours.
As a result of successful work, they later extended their research activities to the therapy of these diseases. The focus was on slowing down the formation of metastases in liver, breast and prostate cancer as well as leukaemia. In 2011, the researchers achieved a breakthrough: their treatment methods showed clinically significant results on patients for the first time.
Scientific Achievements
Pospelov holds a total of 16 patents in the fields of genetics, immunology, intravascular surgery. His most significant research contributions include the process for isolating specific miRNA types from exosome-containing biological fluids and, building on this, the process for producing an exosome-containing agent for metastasis suppression. In this process, an individual preparation for combating the tumour is produced on the basis of the specific exosomes of the tumour. The preparation enables the patient's T-lymphocytes to recognise and destroy the cancer cells. Unlike chemotherapy, this only destroys malignant cells, which makes it much better tolerated and has fewer contraindications.
This procedure is mainly used to combat metastases in lung, prostate and liver cancer. It is based on the research findings of Randy Schekmann, who received the Nobel Prize for Medicine in 2013. Pospelov followed this up by developing a science-practice method of immunotherapy using general exosomes made from biological fluids. Part of the income from the patents goes to Pospelov's charity "Law, Justice and Mercy".